Paradigm Capital Management Inc. NY Makes New $39.77 Million Investment in DENTSPLY SIRONA Inc. $XRAY

Paradigm Capital Management Inc. NY bought a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,748,800 shares of the medical instruments supplier’s stock, valued at approximately $39,775,000. DENTSPLY SIRONA comprises 1.1% of Paradigm Capital Management Inc. NY’s investment portfolio, making the stock its 21st largest position. Paradigm Capital Management Inc. NY owned 1.88% of DENTSPLY SIRONA at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in DENTSPLY SIRONA during the 1st quarter worth about $26,000. Eurizon Capital SGR S.p.A. bought a new stake in shares of DENTSPLY SIRONA during the fourth quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of DENTSPLY SIRONA by 337.9% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,122 shares in the last quarter. Farther Finance Advisors LLC raised its position in DENTSPLY SIRONA by 119.1% in the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 2,051 shares during the last quarter. Finally, Performa Ltd US LLC raised its position in DENTSPLY SIRONA by 116.1% in the 4th quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 2,283 shares during the last quarter. 95.70% of the stock is owned by institutional investors.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Brian T. Gladden bought 9,985 shares of the stock in a transaction on Monday, June 15th. The stock was purchased at an average price of $10.02 per share, with a total value of $100,049.70. Following the completion of the purchase, the director owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. This trade represents a 19.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Brian P. Mckeon bought 10,000 shares of the business’s stock in a transaction on Friday, June 12th. The stock was purchased at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the completion of the acquisition, the director owned 10,000 shares of the company’s stock, valued at approximately $101,200. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 35,160 shares of company stock valued at $351,179. Corporate insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Stock Down 0.3%

Shares of DENTSPLY SIRONA stock opened at $10.89 on Tuesday. The business has a fifty day simple moving average of $12.04 and a 200 day simple moving average of $11.79. The stock has a market cap of $2.17 billion, a PE ratio of -3.96, a price-to-earnings-growth ratio of 1.38 and a beta of 0.85. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA Inc. has a 12 month low of $9.40 and a 12 month high of $14.86.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The company’s quarterly revenue was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts predict that DENTSPLY SIRONA Inc. will post 1.41 EPS for the current year.

Analyst Ratings Changes

XRAY has been the topic of a number of recent research reports. Piper Sandler increased their price objective on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. BMO Capital Markets restated a “market perform” rating and set a $13.00 target price on shares of DENTSPLY SIRONA in a research report on Friday, August 7th. Barrington Research set a $15.00 price target on DENTSPLY SIRONA in a report on Monday, August 10th. UBS Group dropped their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Finally, Mizuho reduced their target price on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $13.54.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.